Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up
Year: 2017
Type: conference-abstract
Source: Blood
Authors: Carlo Gambacorti-Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Iryna Dyagil, Natalia Glushko, Dragana Milojkovic, Philipp D. le Coutre, Valentín García Gutiérrez, Rocco J. Crescenzo, Eric Leip, Nathalie Bardy-Bouxin, Andrea Hochhaus, Timothy H. Brümmendorf, Jorge E. Cortes
Institutions: University of Milano-Bicocca, University of Utah, Memorial Sloan Kettering Cancer Center, Singapore General Hospital, Duke-NUS Medical School, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, National Research Center for Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine, Hammersmith Hospital, Imperial College London, Charité - Universitätsmedizin Berlin, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Pfizer (United States), Pfizer (France), Jena University Hospital, Universitätsklinikum Aachen, RWTH Aachen University, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3148401066